Pricing Log in Create free account
Friday 6 November 2026 Export CERS’s income statement to Excel — free account

Cerus Corporation

CERS Healthcare Medical Devices

Revenue
+6.28%
EPS
−2,800.0%
Free cash flow
+2,471.3%
Total debt
−25.4%

Quarter to September 2026, against a year earlier

2.06 0.07 −3.29%
Market cap
$430.2M
P/E
0.0×
Fwd P/E
−65.1×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.99
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 9 — 2 5 1 1 — — —
Insider Ownership 5.24%

Capital & Financial Ratios $m

Size
Market Cap 430.16
Revenue ttm 251.79
Net income ttm (7.39)
Free cash flow ttm 0.49
Net debt Q 6.24
Valuation
P/E 0.00
Forward P/E (65.10) (negative: loss-making)
Price / sales 1.71
Forward P/S Powerpack
Price / FCF 869.48
Price / book 5.62
Financial health
Current ratio Q 1.96 (at or above 1.5: strong)
Debt / equity Q 0.83
Interest coverage Q 0.31
Growth
Revenue growth Q +6.28% (above 0%: growing)
Operating income growth Q −69.01% (below 0%: shrinking)
EPS, this year +65.62% (at or above 15%: strong)
EPS, next year A +100.00% (at or above 15%: strong)
Revenue, next year A +6.50%
EPS, past 5 yrs —
EPS, next 5 yrs A +54.33% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 6.0×; over the ten years it ranged from 1.2× in 2025 to 19.7× in 2016.
P/S against its own 10 years 16.61%
10-year low 10-year high
P/B against its own 10 years 11.77%
10-year low 10-year high
EV/Sales against its own 10 years 16.32%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 66 80 83 57
Receivables 36 30 30 31
Inventory 40 38 56 65
Other — — — —
144 152 174 157
2023 2024 2025 Q'26
Payables 24 22 28 26
ST’ Debt 20 19 43 29
Other — — — —
68 64 101 80

Compound Annual Growth %

10y 5y 3y
Sales 21.19% 15.40% 7.48%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (3.71%) (8.95%) (1.78%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.01 Actual 0.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.02 0.00 Beat by 0.02
Q4 FY25 −0.01 −0.01 Met by 0.00
Q1 FY26 −0.03 −0.01 Beat by 0.02
Q3 FY26 −0.01 0.00 Beat by 0.01
Q4 FY26 −0.01 — Reports 1 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.01) (0.01) 0.00 — —
’25 (0.04) (0.03) 0.00 (0.01) (0.08)
’24 (0.05) (0.03) (0.02) (0.01) (0.11)
’23 (0.09) (0.07) (0.04) (0.01) (0.21)
’22 (0.07) (0.05) (0.05) (0.08) (0.24)
’21 (0.10) (0.09) (0.07) (0.05) (0.32)
’20 (0.10) (0.09) (0.08) (0.09) (0.37)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 60 63 64 — —
’25 49 60 60 65 234
’24 43 51 51 57 201
’23 38 48 47 53 187
’22 43 48 46 51 188
’21 30 38 42 50 160
’20 25 27 29 34 114
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) 3 — —
’25 (1) (2) 2 6 5
’24 2 0 4 5 11
’23 (8) (9) (10) (15) (43)
’22 (21) 0 (2) (2) (26)
’21 (17) (9) (7) (1) (34)
’20 (20) (8) (5) (9) (42)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (4) 2 — —
’25 (1) (3) 0 5 1
’24 1 0 3 4 9
’23 (10) (9) (13) (15) (48)
’22 (22) 0 (3) 37 12
’21 (18) (9) (7) (2) (35)
’20 (20) (8) (5) (9) (43)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 39 51 76 94 114 160 188 187 201 234 252 +21.9% 249 272 295 +8.1%
Gross margin, % 48.33 56.10 58.40 64.36 63.98 60.21 60.20 62.54 59.89 59.86 56.66 +11.5 pt
EBT (63) (57) (57) (71) (60) (54) (42) (37) (21) (15) (7) (14.5%)
EBT margin, % (159.72) (110.47) (75.39) (75.69) (52.14) (33.89) (22.48) (19.98) (10.31) (6.54) (2.79) +153.2 pt
Net income (63) (61) (58) (71) (60) (54) (43) (38) (21) (16) (7) (14.3%)
Per share, $
Per share, $ Revenue 0.39 0.47 0.58 0.67 0.70 0.93 1.07 1.04 1.09 1.23 1.25 +13.7%
Earnings (0.62) (0.56) (0.44) (0.51) (0.37) (0.32) (0.24) (0.21) (0.11) (0.08) (0.04) (20.3%)
Cash flow (0.53) (0.48) (0.24) (0.47) (0.25) (0.20) (0.15) (0.24) 0.06 0.03 0.02 n/m
Capex (0.01) 0.00 (0.01) (0.06) (0.01) (0.01) 0.22 (0.03) (0.02) (0.02) (0.01) +15.2%
Free cash flow (0.53) (0.49) (0.25) (0.53) (0.26) (0.20) 0.07 (0.26) 0.05 0.01 0.00 n/m
Book value 0.57 0.36 0.64 0.41 0.63 0.50 0.39 0.30 0.31 0.34 0.38 (5.5%)
Shares, m 102 108 132 140 164 171 177 180 185 191 197 +7.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 11.23 7.51 8.78 6.29 9.93 7.31 3.51 2.08 1.41 1.68 1.71 6.0
P/B 7.63 9.89 7.90 10.34 10.93 13.62 9.63 7.29 5.00 6.04 5.62 8.8
EV/Sales 9.90 7.01 7.62 5.85 9.18 6.94 3.33 2.16 1.43 1.68 1.73 5.5
EV/FCF (7.18) (6.84) (17.90) (7.37) (24.16) (31.77) 50.28 (8.44) 33.79 355.26 882.11 33.6
Cash, $m
Cash, $m Operating cash flow (54) (52) (31) (65) (42) (34) (26) (43) 11 5 3 n/m
Capex (1) 0 (1) (9) (2) (1) 38 (5) (3) (4) (3) +23.4%
Free cash flow (54) (53) (32) (74) (43) (35) 12 (48) 9 1 0 n/m
Balance, $m
Balance, $m Working capital 67 67 94 78 123 109 53 77 88 74 77 +1.0%
Net debt (52) (31) (88) (41) (85) (60) (32) 14 4 1 6 n/m
Shareholders’ equity 58 39 85 57 104 86 69 53 57 65 76 +1.3%
Returns, %
Returns, % ROA (51.80) (60.07) (43.99) (43.31) (30.94) (23.70) (18.78) (18.03) (10.49) (7.39) (3.48) +44.4 pt
ROIC (693.97) (447.11) 0.00 (262.55) (199.05) (119.11) (58.82) (27.87) (14.67) (8.22) (1.87) +685.8 pt
ROE (82.47) (125.27) (93.25) (100.65) (74.42) (57.41) (55.49) (61.45) (37.92) (25.65) (10.56) +56.8 pt
People
People Employees 204 215 240 254 270 294 309 288 281 275 — +3.4%
Revenue/emp, $m 0.19 0.24 0.32 0.37 0.42 0.54 0.61 0.65 0.72 0.85 — +17.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Cerus Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SGHT Sight Sciences, Inc. $537.7M — (loss-making) — (loss-making) +25.20% (above 0%: growing) n/m +72.21% (above 0%: growing) 85.94% (24.59%) Compare
DCTH Delcath Systems, Inc. $502.8M 1,455× — (loss-making) +20.60% (above 0%: growing) −12.50% (below 0%: shrinking) −24.45% (below 0%: shrinking) 89.75% 8.22% Compare
NPCE NeuroPace, Inc. $435.6M — (loss-making) — (loss-making) −2.95% (below 0%: shrinking) n/m −78.70% (below 0%: shrinking) 82.83% (22.53%) Compare
CERS Cerus Corporation $430.2M — (loss-making) — (loss-making) +6.28% (above 0%: growing) n/m +2,471.28% (above 0%: growing) 57.12% 0.60%
BWAY Brainsway Ltd. Sponsored ADR $427.1M 21.2× — (loss-making) +35.43% (above 0%: growing) +40.00% (above 0%: growing) −51.68% (below 0%: shrinking) 74.62% 13.98% Compare
SI Shoulder Innovations, Inc. $424.1M — (loss-making) — (loss-making) +37.73% (above 0%: growing) n/m +38.63% (above 0%: growing) 78.47% (46.92%) Compare
SENS Senseonics Holdings, Inc. $422.5M — (loss-making) — (loss-making) +117.82% (above 0%: growing) n/m −223.24% (below 0%: shrinking) 59.10% (248.48%) Compare
MASS 908 Devices Inc. $419.5M — (loss-making) — (loss-making) +23.31% (above 0%: growing) n/m +150.95% (above 0%: growing) 51.90% (79.69%) Compare
SSII SS Innovations International, Inc. $380.9M — (loss-making) — (loss-making) +39.39% (above 0%: growing) n/m −16.62% (below 0%: shrinking) 50.94% (16.29%) Compare
Median of peers $425.6M — — +30.32% — −20.53% 76.55% (23.56%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 22 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.79m 5.77m 29.77
2024 2.98m 2.06m 22.25
2023 3.66m 760.32k 31.21
2022 5.26m 120.29k 52.75
2021 5.18m 5.13m 98.41

Ownership

Directors and executive officers, together 5.30%
ARK Investment Management LLC 9.60%
BlackRock, Inc. 6.90%
Baker Bros. Advisors LP 5.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cerus Corporation (CERS) Latest News

3 Nov

Impact 3 · · Moby
Impact 3 · · The Motley Fool
Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com

2 Nov

Impact 4 · · Business Wire
Impact 3 · · MarketBeat
Impact 3 · · Business Wire

19 Oct

Impact 3 · · Business Wire

14 Oct

Impact 3 · · Business Wire

30 Jul

Impact 3 · · MarketBeat transcript
Impact 3 ·

16 Jun

Impact 4 ·

8 Jun

Impact 3 · · Business Wire

1 May

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

30 Apr

Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat
Impact 3 · · Business Wire

27 Apr

Impact 4 · · Business Wire

16 Mar

Impact 4 · · Business Wire

7 Mar

Impact 4 · · MarketBeat

3 Mar

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

2 Mar

Impact 4 · · The Motley Fool transcript
Impact 4 · · Associated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceSimply Wall St.Associated Press FinanceAssociated Press Finance
Impact 4 · · Business Wire
Impact 3 · · MarketBeat

22 Jan

Impact 4 · · Business Wire

13 Jan

Impact 4 · · Simply Wall St.

11 Jan

Impact 4 · · Business WireMT NewswiresBarchartMarketBeatMT NewswiresSimply Wall St.Simply Wall St.MT Newswires
stockrow.com/CERS · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com